{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:17:46Z","timestamp":1793830666485,"version":"4.6.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Thomas Kirch Stiftung"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Assessment of postoperative tumor burden is essential in IDH-wildtype glioblastoma. The RANO resect classification stratifies patients based on residual tumor volume on postoperative MRI.O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET can detect metabolically active tumor-suspicious tissue invisible on MRI. Its additional prognostic contribution remains ill-defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective bicentric study analyzed 140 patients with newly diagnosed IDH-wildtype glioblastoma and postoperative MRI and [18F]FET PET. MRI-derived residual tumor was classified by RANO resect; PET-derived volumes were defined using PET RANO 1.0 criteria. Spatial concordance was quantified using Dice coefficients. Prognostic associations were assessed by Cox regression. PET\u2019s incremental prognostic value was evaluated using a 2-stage framework comparing MRI-only, PET-augmented, and fully adjusted models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Postoperative PET-defined volumes were substantially larger than MRI-defined volumes and showed minimal spatial overlap across RANO resect classes. PET-, T1CE-, and T2\/FLAIR-based tumor volumes were independently associated with OS. Residual PET volume was associated with increasing mortality risk and remained independently associated with OS (HR 1.021 per cm\u00b3, **P = .002). In an imaging-only model, addition of PET improved time-dependent discrimination (\u0394AUC(t) 0.03-0.07) and increased Harrell\u2019s C (\u0394C \u2248 0.03), indicating improved prognostic discrimination. In the fully adjusted model, adding PET significantly improved model fit (*P = .0049), indicating prognostic information beyond MRI-derived tumor burden and clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Postoperative PET visualized tumor-suspicious volume not identified by MRI and provided additional prognostic information. These findings support the potential role of PET for refined postoperative risk stratification, while prospective studies are needed to determine whether PET-informed postoperative management improves clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag212","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:15:10Z","timestamp":1788509710000},"source":"Crossref","is-referenced-by-count":1,"title":["Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-8745","authenticated-orcid":false,"given":"Jens","family":"Blobner","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-4744","authenticated-orcid":false,"given":"Katharina J","family":"Schmidbauer","sequence":"additional","affiliation":[{"name":"Department of Neurology, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-5555","authenticated-orcid":false,"given":"Michael","family":"M\u00fcther","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Muenster , Muenster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3746-9393","authenticated-orcid":false,"given":"Wolfgang","family":"Roll","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Muenster , Muenster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elene","family":"Nikolaishvili","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-2265","authenticated-orcid":false,"given":"Jonas","family":"Reis","sequence":"additional","affiliation":[{"name":"Institute for Neuroradiology, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-3874","authenticated-orcid":false,"given":"Maximilian J","family":"Mair","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna,","place":["Austria"]},{"name":"Department of Nuclear Medicine, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8643-0141","authenticated-orcid":false,"given":"Niklas","family":"Thon","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"Department of Neurosurgery, Knappschaft University Hospital Bochum , Bochum,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-8960","authenticated-orcid":false,"given":"Stephan","family":"Schoenecker","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-6910","authenticated-orcid":false,"given":"Patrick N","family":"Harter","sequence":"additional","affiliation":[{"name":"Center for Neuropathology and Prion Research, Medical Faculty, Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Kalasauskas","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-0927","authenticated-orcid":false,"given":"Louisa","family":"von Baumgarten","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"Department of Neurology, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-6046","authenticated-orcid":false,"given":"Rudolf A","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-7543","authenticated-orcid":false,"given":"Florian","family":"Ringel","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9103-2357","authenticated-orcid":false,"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Muenster , Muenster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1756-423X","authenticated-orcid":false,"given":"Joerg-Christian","family":"Tonn","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-5310","authenticated-orcid":false,"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , Munich,","place":["Germany"]},{"name":"Department of Neurosurgery, FAU University Hospital of the Friedrich-Alexander-University , Erlangen,","place":["Germany"]},{"name":"Department of Neurosurgery, TUM University Hospital, Technical University Munich , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital of the Ludwig-Maximilians-University Munich , Munich,","place":["Germany"]},{"name":"German Consortium for Translational Cancer Research (DKTK), Partner Site Munich , Heidelberg,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2026100122371867000_noag212-B1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100122371867000_noag212-B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100122371867000_noag212-B3","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B5","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(24)00130-X","article-title":"The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a review by the RANO resect group","volume":"25","author":"Karschnia","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026100122371867000_noag212-B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/neuonc\/noad189","article-title":"RANO 2.0: the revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2026100122371867000_noag212-B8","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026100122371867000_noag212-B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/neuonc\/noae208","article-title":"Measurable disease as baseline criterion for response assessment in glioblastoma: a comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments","volume":"27","author":"M\u00fcller","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B10","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026100122371867000_noag212-B11","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S1470-2045(25)00193-7","article-title":"Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas","volume":"26","author":"Galldiks","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026100122371867000_noag212-B12","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1038\/s41467-023-39731-8","article-title":"Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma","volume":"14","author":"Harat","year":"2023","journal-title":"Nat Commun"},{"key":"2026100122371867000_noag212-B13","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00259-024-06601-4","article-title":"Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy","volume":"51","author":"Chaban","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100122371867000_noag212-B14","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/j.wneu.2018.09.139","article-title":"Can early postoperative O-(2-(18F)fluoroethyl)-l-tyrosine positron emission tomography after resection of glioblastoma predict the location of later tumor recurrence?","volume":"121","author":"Buchmann","year":"2019","journal-title":"World Neurosurg"},{"key":"2026100122371867000_noag212-B15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00259-018-4180-3","article-title":"Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma","volume":"46","author":"Lundemann","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100122371867000_noag212-B16","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.eanmj.2025.100008","article-title":"EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!","volume":"1","author":"Verger","year":"2025","journal-title":"The EANM Journal"},{"key":"2026100122371867000_noag212-B17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/neuonc\/nov095","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1227\/NEU.0b013e318223f5a7","article-title":"Application of novel response\/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) working group","volume":"70","author":"Vogelbaum","year":"2012","journal-title":"Neurosurgery"},{"key":"2026100122371867000_noag212-B19","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S1470-2045(23)00453-9","article-title":"A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups","volume":"24","author":"Karschnia","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026100122371867000_noag212-B20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00259-016-3494-2","article-title":"The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma","volume":"44","author":"Poulsen","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100122371867000_noag212-B21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"2026100122371867000_noag212-B22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/neuonc\/nov148","article-title":"Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis","volume":"18","author":"Dunet","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.nicl.2016.12.020","article-title":"The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy","volume":"13","author":"Galldiks","year":"2017","journal-title":"Neuroimage Clin"},{"key":"2026100122371867000_noag212-B24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.nucmedbio.2013.05.001","article-title":"Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas","volume":"40","author":"Piroth","year":"2013","journal-title":"Nucl Med Biol"},{"key":"2026100122371867000_noag212-B25","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s00259-019-04656-2","article-title":"Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET\/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study","volume":"47","author":"Song","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100122371867000_noag212-B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11060-021-03844-1","article-title":"18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III\/IV glioma: moving towards a multimodal imaging-guided resection","volume":"155","author":"Ort","year":"2021","journal-title":"J Neurooncol"},{"key":"2026100122371867000_noag212-B27","doi-asserted-by":"publisher","first-page":"14554","DOI":"10.1038\/s41598-021-93986-z","article-title":"Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on (11)C-methionine PET: a retrospective, single-center study","volume":"11","author":"Hirono","year":"2021","journal-title":"Sci Rep"},{"key":"2026100122371867000_noag212-B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/neuonc\/noaf217","article-title":"EANS-EANO guidelines on the extent of resection in gliomas","volume":"28","author":"Goldbrunner","year":"2026","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B29","doi-asserted-by":"publisher","first-page":"100010","DOI":"10.1016\/j.eanmj.2025.100010","article-title":"Systematic analysis of amino acid PET use in Germany: strategic considerations for widespread clinical application","volume":"1","author":"Albert","year":"2025","journal-title":"The EANM Journal"},{"key":"2026100122371867000_noag212-B30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0000000000001262","article-title":"Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM","volume":"84","author":"Suchorska","year":"2015","journal-title":"Neurology"},{"key":"2026100122371867000_noag212-B31","doi-asserted-by":"publisher","first-page":"30011","DOI":"10.1038\/s41598-025-15185-4","article-title":"Tumor-specific PET tracer imaging and contrast-enhanced mri based tumor volume differences inspection of glioblastoma patients","volume":"15","author":"Abbasi","year":"2025","journal-title":"Sci Rep"},{"key":"2026100122371867000_noag212-B32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/cancers14051103","article-title":"PET imaging in neuro-oncology: an update and overview of a rapidly growing area","volume":"14","author":"Verger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026100122371867000_noag212-B33","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026100122371867000_noag212-B34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(25)00642-4","article-title":")F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA\/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial","volume":"27","author":"Grosu","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026100122371867000_noag212-B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/noae209","article-title":"Point\/counterpoint: the role of reirradiation in recurrent glioblastoma","volume":"27","author":"Rahman","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026100122371867000_noag212-B36","doi-asserted-by":"publisher","first-page":"20828","DOI":"10.1038\/s41598-021-00193-x","article-title":"Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement","volume":"11","author":"Rosen","year":"2021","journal-title":"Sci Rep"},{"key":"2026100122371867000_noag212-B37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2967\/jnumed.120.254243","article-title":"Early treatment response assessment using (18)F-FET PET compared with Contrast-Enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy","volume":"62","author":"Ceccon","year":"2021","journal-title":"J Nucl Med"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag212\/70951957\/noag212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag212\/70951957\/noag212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:37:23Z","timestamp":1790908643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag212\/8785302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag212","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"noag212"}}